Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes
Authors:
- Maeve Soto PérezMPMaeve Soto Pérez
- Jorge Rodríguez-CapitánJRJorge Rodríguez-Capitán
- Juan Antonio Requena-IbáñezJRJuan Antonio Requena-Ibáñez
- Carlos G. Santos-GallegoCSCarlos G. Santos-Gallego
- M. Urooj ZafarMZM. Urooj Zafar
- Ginés EscolarGEGinés Escolar
- Donna ManciniDMDonna Mancini
- Sumeet MitterSMSumeet Mitter
- David LamDLDavid Lam
- Johanna P. ContrerasJCJohanna P. Contreras
- Icilma FergusIFIcilma Fergus
- Farah Atallah-LajamFAFarah Atallah-Lajam
- 15 June 2023
- journal article
- review article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 39 (1) , 155-164
Abstract
Heart failure with preserved ejection fraction (HFpEF) is now the most common form of heart failure (HF). This syndrome is associated with an elevated morbi-mortality, and effective therapies are urgently needed. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the first pharmacological class that has demonstrated to reduce hospitalization and cardiovascular mortality in large clinical trials in HFpEF. Furthermore, the dual SGLT 1/2 inhibitor sotagliflozin has shown a reduction in cardiovascular outcomes in diabetic HF patients, regardless of ejection fraction Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) Trial, and prevents the development of HF in patients with diabetes and chronic kidney disease Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED) trial. The major objective of the Sotagliflozin in Heart Failure With Preserved Ejection Fraction Patients (SOTA-P-CARDIA) trial (NCT05562063) is to investigate whether the observed cardiorenal benefits of sotagliflozin in HF patients with diabetes can be extended to a non-diabetic population. The SOTA-P-CARDIA is a prospective, randomized, double-blinded, placebo-controlled study that will randomize non-diabetic patients with the universal definition of HFpEF (ejection fraction > 50% assessed the day of randomization). Qualifying patients will be randomized, in blocks of 4, to receive either sotagliflozin or placebo for a period of 6 months. The primary outcome is changes in left ventricular mass by cardiac magnetic resonance from randomization to end of the study between the groups. Secondary end points include changes in peak VO2; myocardial mechanics, interstitial myocardial fibrosis, and volume of epicardial adipose tissue; distance in the 6-min walk test; and quality of life. Finally, the authors expect that this trial will help to clarify the potential benefits of the use of sotagliflozin in non-diabetic HFpEF patients.Keywords
Funding Information
- 'la Caixa' Foundation (LCF/BQ/EU21/11890141)
- Lexicon Pharmaceuticals, Inc.
This publication has 43 references indexed in Scilit:
- Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic RiskJACC, 2018
- Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the MyocardiumJACC, 2018
- Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to dateDrug Design, Development and Therapy, 2017
- Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological targetInternational Journal of Cardiology, 2017
- 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart FailureEuropean Journal of Heart Failure, 2016
- Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/ReperfusionCirculation, 2016
- Epidemiology of Heart Failure: The Prevalence of Heart Failure and Ventricular Dysfunction in Older Adults Over Time. a Systematic ReviewEuropean Journal of Heart Failure, 2016
- Characterizing preclinical models of ischemic heart failure: differences between LAD and LCx infarctionsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2014
- A Novel Paradigm for Heart Failure With Preserved Ejection FractionJACC, 2013
- High-Dose Allopurinol Reduces Left Ventricular Mass in Patients With Ischemic Heart DiseaseJACC, 2013